This statistic shows the number of registrations of newly diagnosed cases of ovarian cancer in England in 2022, by age group. The most affected age group was among 75 to 79 year olds, with 908 cases reported in 2022.

This dataset, titled "Ovarian Cancer Risk and Progression Data," contains 200,100 hourly patient records collected between January 2019 and December 2024. The data originates from a healthcare repository hosted by a leading research institute in Munich, Germany. It includes an extensive array of features spanning clinical, genetic, imaging, and demographic dimensions. The dataset represents a diverse population from Munich's urban and suburban regions, ensuring broad demographic and socioeconomic variety. Ethical protocols were strictly followed, and all personal identifiers were removed to protect patient privacy. This dataset provides invaluable resources for ovarian cancer risk prediction, cancer progression modeling, and advanced machine learning research.

Dataset Composition: The dataset encompasses the following categories of features:

Clinical Features:

Age: Patient's age at diagnosis, ranging from 18 to 90 years. BMI: Body Mass Index values (15–50), indicating health and weight status. Comorbidities: Presence of additional diseases, with 30% of patients reporting comorbid conditions. Symptoms: Binary feature indicating the presence of symptoms like abdominal pain or bloating. CA-125 Levels: A critical biomarker for ovarian cancer, ranging from 0 to 200. Cancer Stage: Classification into Stages 0 to IV, reflecting disease progression. Histopathology: Cancer subtypes (serous, mucinous, clear cell) based on tissue analysis. Previous Treatments: History of chemotherapy, surgery, or radiation. Menstrual History: Regular or irregular menstrual patterns. Demographic Features:

Ethnicity: Patient's ethnic background (Caucasian, Asian, African, Hispanic). Smoking & Alcohol: Lifestyle habits, with binary indicators. Residence: Urban or rural living environments. Socioeconomic Status: Economic categories (Low, Middle, High). Genetic Features:

BRCA Mutation: Binary indicator for BRCA1/BRCA2 mutations. Gene Expression: Normalized gene activity values. SNP Status: Presence of significant single nucleotide polymorphisms. DNA Methylation & miRNA Levels: Continuous variables capturing molecular markers. Imaging-Derived Features:

Tumor Size & Location: Dimensions and anatomical origin (Ovary, Fallopian Tube, Peritoneum). Radiomic Features: Texture, intensity, and shape metrics derived from imaging. Enhancement Patterns: Contrast enhancement in imaging. Doppler Velocity: Blood flow velocity within tumors. Reproductive and Hormonal Features:

Parity: Number of pregnancies (0–3). Oral Contraceptives & Hormone Therapy: Binary indicators for usage history. Menarche & Menopause Age: Age at the onset of menstruation and menopause. Target Variables:

Risk Label: Multi-class classification (0: No Risk, 1: Low Risk, 2: Medium Risk, 3: High Risk). Progression Probability: Continuous variable (0–1) representing the likelihood of disease progression. Dataset Utility: This dataset is curated for advancing research in ovarian cancer risk assessment and progression modeling. It is designed to support studies leveraging machine learning and deep learning techniques, providing a real-world, comprehensive feature set. Applications include multi-modal classification, risk stratification, and personalized medicine development. The high-dimensional and balanced representation ensures robust training and evaluation for predictive models. This dataset can be instrumental for researchers aiming to improve ovarian cancer diagnosis and intervention strategies.

This statistic shows the 10-year probability of a women developing ovarian cancer in the United States as of 2018. According to the data, a women at the age of ** has a *** percent probability of developing ovarian cancer within the next 10 years. However, a women at the age of ** has a *** percent probability of developing ovarian cancer within the next 10 years.

BackgroundThe growing burden of ovarian cancer is attracting widespread attention; the impact factors and the evolution trend of ovarian cancer burden need to be further studied.MethodsOvarian cancer disease burden data for Chinese women were obtained from the Global Burden of Disease study 2021. We performed Age-Period-Cohort (APC) analysis to evaluate evolution trends across age, period, and cohort dimensions and identify contributing factors. Using the Bayesian Age-Period-Cohort (BAPC) model, we projected incidence and mortality trends through 2040.ResultsIn 2021, China recorded approximately 41,240 new ovarian cancer cases and 25,140 related deaths. From 1990 to 2021, age-standardized rates (ASRs) for incidence, mortality, and disability-adjusted life years fluctuated but increased steadily after 2015, with annual percentage changes of 1.6% (95%CI: 1.4%, 1.8%), 1.6% (95%CI: 1.4%, 1.9%), and 1.5% (95%CI: 1.3%, 1.6%), respectively. The APC model revealed a significant age effect with peak incidence occurring at 65–69 years; a period effect showing incidence and mortality rates resurged after 2015; and the cohort effects demonstrating bimodal incidence peaks in the birth cohorts of 1910–1914 and 1935–1939. Specifically, a 1% increase in the obesity rate was associated with a 3.06 (95%CI: 0.84, 5.28; p = 0.007) per 100,000 rise in ovarian cancer incidence. BAPC projections suggest that the ASRs of incidence and mortality of ovarian cancer in China will continue rising through 2040, possibly exceeding global trends.ConclusionsThe burden of ovarian cancer in China remains significant; the increasing obesity rate in women may be a driver. The ovarian cancer burden has resurged in China since 2015, and it is projected to continue increasing by 2040.

Ovarian cancer is one of the most lethal gynecological cancers. Despite diagnosis and treatment advances, survival rates have not increased over the past 32 years. This study estimated and reported the global burden of ovarian cancer during the past 32 years to inform preventative and control strategies. We examined ovarian cancer incidence, mortality, and disability-adjusted life years (DALYs) using age-standardized rates from the Global Burden of Disease, Injuries, and Risk Factors Study 2021. high body mass index and occupational asbestos exposure were linked with death and DALYs. Data are presented as averages with 95 % uncertainty intervals (UIs). Indonesia had 13 250 (8 574–21 565) ovarian cancer cases in 2021, with 5 296 (3 520–8958) deaths and 186 917 (121 866–309 820) DALYs. The burden increased by 233.53 % for new cases, 221.95 % for mortalities, and 206.65 % for DALYs. The age-standardized rate also increased from 1990 to 2021. Ovarian cancer burden increased with age but declined in the 50+ year age group. According to the sociodemographic index, the gross domestic product per capita and number of obstetricians and oncologic gynecologists in provinces showed different trends. Indonesian ovarian cancer rates are rising despite gynecologic oncologists in 24 of 34 provinces. These findings will help policymakers and healthcare providers identify ovarian cancer prevention and control gaps.

According to the Department of Health of the government of Hong Kong, the age-standardized death rate of ovarian and peritoneal cancer in Hong Kong was around 3.4 per 100,000 female population in 2023. This indicated an increase in fatality rate compared to the previous years.

This statistic shows the death rate of ovary cancer per 100,000 age-adjusted population in the United States from 1999 to 2021. The maximum death rate in the given period for ovary cancer stood at nine in 2001 and 2002.

Ovarian Cancer Market Outlook

The global ovarian cancer market size was estimated to be USD 3.5 billion in 2023, with a projected compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. This robust growth is driven by several factors, including advancements in medical technology, increasing awareness about early diagnosis, and the rising prevalence of ovarian cancer worldwide. By 2032, the market is expected to reach approximately USD 6.5 billion, underscoring the critical need for innovative treatment strategies and accessible healthcare solutions across various regions. Such growth is largely attributed to increasing investments in research and development, leading to novel therapeutic options and the expansion of healthcare infrastructure globally.

One of the significant growth factors for the ovarian cancer market is the increasing incidence and prevalence of the disease. Ovarian cancer remains one of the leading causes of cancer-related deaths among women, primarily due to late diagnosis. Early-stage ovarian cancer often presents with nonspecific symptoms, resulting in late-stage detection when treatment options are limited. This challenge has prompted greater focus on developing better diagnostic tools and screening methods, which is expected to drive market growth. Additionally, lifestyle factors, genetic predispositions, and increasing age are contributing to the rising incidence rates, further scaling the demand for effective treatment solutions.

The advent of precision medicine is another pivotal factor propelling the growth of the ovarian cancer market. Precision medicine involves tailoring healthcare treatments to individual patients based on genetic, environmental, and lifestyle factors. This approach is gaining traction as it promises to improve treatment efficacy and patient outcomes. The development of targeted therapies, which aim to attack specific cancer cells while sparing healthy ones, represents a significant advancement. These therapies are becoming increasingly integrated into standard treatment protocols, supported by favorable clinical outcomes and regulatory approvals. As a result, the market is witnessing an influx of targeted therapy options, offering renewed hope for patients and driving market expansion.

Increasing awareness and advocacy efforts are also playing a crucial role in the growth of the ovarian cancer market. Various organizations and stakeholders are actively involved in raising awareness about ovarian cancer symptoms, risk factors, and the importance of regular medical check-ups. Such initiatives have led to greater patient education and improved healthcare-seeking behaviors, contributing to earlier diagnoses and better management of the disease. Additionally, governmental and non-governmental funding for ovarian cancer research is bolstering the market by facilitating the development of new drugs and treatment methodologies. These collaborative efforts are poised to sustain the market's growth trajectory in the coming years.

The development and availability of Gynaecological Cancer Drugs are pivotal in addressing the treatment needs of ovarian cancer patients. These drugs are specifically designed to target the unique biological characteristics of gynecological cancers, including ovarian cancer, providing more effective and tailored treatment options. The innovation in this field is driven by extensive research and development efforts, focusing on improving drug efficacy and minimizing side effects. As a result, patients have access to a broader range of therapeutic options, enhancing their chances of successful treatment outcomes. The integration of these drugs into standard treatment protocols is supported by clinical evidence demonstrating their benefits in managing ovarian cancer. As the market for gynaecological cancer drugs continues to expand, it is expected to play a significant role in the overall growth of the ovarian cancer treatment landscape.

Regionally, North America dominates the ovarian cancer market, owing to its well-established healthcare infrastructure, high prevalence of the disease, and extensive research activities. The presence of leading pharmaceutical companies and research institutions further supports market growth in this region. Europe follows closely, with countries like Germany, France, and the UK making substantial investments in cancer research and treatment. The Asia Pacific region is expected to witness the fastest growth rate, driven by increasing healthcare awareness and improving healthcare infrastructure. Rapid urbanization and e

ObjectiveOvarian cancer in Black women is common in many West African countries but is relatively rare in North America. Black women have worse survival outcomes when compared to White women. Ovarian cancer histotype, diagnosis, and age at presentation are known prognostic factors for outcome. We sought to conduct a preliminary comparative assessment of these factors across the African diaspora.MethodsPatients diagnosed with ovarian cancer (all histologies) between June 2016-December 2019 in Departments of Pathology at 25 participating sites in Nigeria were identified. Comparative population-based data, inclusive of Caribbean-born Blacks (CBB) and US-born Blacks (USB), were additionally captured from the International Agency for Research on Cancer and Florida Cancer Data Systems. Histology, country of birth, and age at diagnosis data were collected and evaluated across the three subgroups: USB, CBB and Nigerians. Statistical analyses were done using chi-square and student’s t-test with significance set at p<0.05.ResultsNigerians had the highest proportion of germ cell tumor (GCT, 11.5%) and sex-cord stromal (SCST, 16.2%) ovarian cancers relative to CBB and USB (p=0.001). CBB (79.4%) and USB (77.3%) women were diagnosed with a larger proportion of serous ovarian cancer than Nigerians (60.4%) (p<0.0001). Nigerians were diagnosed with epithelial ovarian cancers at the youngest age (51.7± 12.8 years) relative to USB (58.9 ± 15.0) and CBB (59.0± 13.0,p<0.001). Black women [CBB (25.2 ± 15.0), Nigerians (29.5 ± 15.1), and USB (33.9 ± 17.9)] were diagnosed with GCT younger than White women (35.4 ± 20.5, p=0.011). Black women [Nigerians (47.5 ± 15.9), USB (50.9 ± 18.3) and CBB (50.9 ± 18.3)] were also diagnosed with SCST younger than White women (55.6 ± 16.5, p<0.01).ConclusionThere is significant variation in age of diagnosis and distribution of ovarian cancer histotype/diagnosis across the African diaspora. The etiology of these findings requires further investigation.

Ovarian Cancer Multimarker Algorithms Market Outlook

According to our latest research, the global ovarian cancer multimarker algorithms market size reached USD 247.8 million in 2024 and is anticipated to expand at a CAGR of 13.4% during the forecast period of 2025 to 2033, ultimately reaching USD 740.2 million by 2033. The market is experiencing robust growth, primarily driven by the increasing incidence of ovarian cancer worldwide, the rising demand for early detection tools, and the adoption of advanced diagnostic technologies that improve patient outcomes.

One of the primary growth factors for the ovarian cancer multimarker algorithms market is the rising prevalence of ovarian cancer globally. With ovarian cancer ranking among the leading causes of cancer-related deaths in women, there is a critical need for more precise and earlier diagnostic solutions. Traditional single-marker tests have shown limitations in sensitivity and specificity, often resulting in late-stage diagnoses when treatment options are limited. The integration of multimarker algorithms, which combine multiple biomarkers and clinical parameters, has been proven to enhance diagnostic accuracy, enabling earlier intervention and improved survival rates. This clinical advantage is compelling healthcare providers and institutions to adopt these technologies, thereby fueling market expansion.

Technological advancements in diagnostic kits, assay platforms, and data analytics are also playing a pivotal role in propelling the market forward. The development of sophisticated analyzers and software capable of processing and interpreting complex biomarker data has made multimarker algorithms more accessible and reliable. Companies are investing heavily in research and development to enhance the sensitivity and specificity of their products, as well as to comply with evolving regulatory standards. The increasing acceptance and integration of artificial intelligence and machine learning in diagnostic algorithms further amplify the accuracy and predictive power of these tools, making them indispensable in modern oncology practices. This technological evolution is expected to continue driving the adoption of ovarian cancer multimarker algorithms across diverse healthcare settings.

Another significant driver is the growing awareness among patients and healthcare professionals regarding the benefits of early detection and personalized medicine in ovarian cancer management. Public and private initiatives aimed at improving cancer screening rates, coupled with favorable reimbursement policies in developed markets, have created a conducive environment for the adoption of multimarker diagnostic solutions. Additionally, the expansion of healthcare infrastructure and diagnostic facilities in emerging economies is opening new avenues for market growth. As healthcare systems worldwide focus on reducing the burden of late-stage cancer diagnoses and optimizing patient outcomes, the demand for advanced diagnostic algorithms is expected to surge.

From a regional perspective, North America continues to dominate the ovarian cancer multimarker algorithms market, accounting for the largest share in 2024, followed by Europe and the Asia Pacific. The region's leadership is attributed to its well-established healthcare infrastructure, high awareness levels, and significant investments in cancer research and diagnostics. Meanwhile, the Asia Pacific region is projected to witness the fastest growth over the forecast period, driven by increasing cancer incidence, improving healthcare access, and rising investments in diagnostic technology. Latin America and the Middle East & Africa are also showing promising growth potential, albeit from a smaller base, as awareness and diagnostic capabilities continue to improve.

Product Type Analysis

The product type segment in the ovarian cancer multimarker algorithms market is comprised of diagnostic kits, assay kits, analyzers, and software. Diagnostic kits represent a significant portion of the market, as they are essential for the rapid and accurate detection of ovarian cancer biomarkers in patient samples. These kits are designed for use in both clinical laboratories and point-of-care settings, offering healthcare professionals reliable tools for early detection and monitoring. The increasing demand for minimally invasive diagnostic options and the growing emphasis on early intervention have driven the adoption of adva

The ovarian cancer therapeutics market is booming, projected to reach $8 billion by 2033. Discover key trends, drivers, and restraints shaping this dynamic market, including advancements in PARP inhibitors, PD-L1 inhibitors, and angiogenesis inhibitors. Learn about leading companies and regional market shares.

Ovarian Cancer Diagnostics and Therapeutics Market Outlook

According to our latest research, the global ovarian cancer diagnostics and therapeutics market size reached USD 5.7 billion in 2024, reflecting robust demand for innovative diagnostics and advanced therapeutic options. The market is projected to expand at a CAGR of 8.9% from 2025 to 2033, reaching a forecasted value of USD 12.1 billion by 2033. This growth is primarily driven by rising ovarian cancer incidence rates, increased awareness, and the advent of precision medicine. As per our comprehensive analysis, advancements in early detection and targeted therapies are significantly reshaping the landscape, offering improved survival outcomes for patients worldwide.

The surge in the ovarian cancer diagnostics and therapeutics market is fueled by a confluence of critical growth factors. Firstly, the global prevalence of ovarian cancer continues to rise, particularly among aging female populations in both developed and developing regions. This demographic shift, coupled with lifestyle-related risk factors such as obesity and reproductive history, has led to an increased patient pool requiring both diagnostic and therapeutic interventions. Moreover, the growing awareness campaigns led by governmental and non-governmental organizations have played a vital role in encouraging women to seek regular screening, thus facilitating early detection and timely treatment. These factors collectively contribute to the expanding market demand for sophisticated diagnostic tools and innovative therapeutic strategies.

Technological advancements in both diagnostics and therapeutics represent another major growth driver for the ovarian cancer diagnostics and therapeutics market. The emergence of liquid biopsies, next-generation sequencing, and advanced imaging modalities has revolutionized early detection, enabling clinicians to identify malignancies at a much earlier stage. In therapeutics, the market is witnessing a paradigm shift toward targeted therapies and immunotherapies, which offer improved efficacy and reduced side effects compared to traditional chemotherapy. The integration of artificial intelligence and machine learning in diagnostic platforms also enhances accuracy and reduces diagnostic turnaround times, further propelling market expansion. These innovations are supported by substantial investments from both public and private sectors, fostering a dynamic ecosystem focused on improving patient outcomes.

A favorable regulatory environment and increased funding for oncology research are further bolstering the ovarian cancer diagnostics and therapeutics market. Regulatory agencies such as the FDA and EMA have streamlined approval pathways for breakthrough therapies and diagnostic tools, expediting their market entry and enhancing patient access to cutting-edge solutions. Additionally, the rise of personalized medicine and companion diagnostics is enabling more tailored treatment approaches, which are particularly valuable in managing the heterogeneity of ovarian cancer. Strategic collaborations among pharmaceutical companies, diagnostic firms, and academic institutions are also accelerating the development and commercialization of novel products, ensuring a steady pipeline of innovations that address unmet clinical needs.

Regionally, North America continues to dominate the ovarian cancer diagnostics and therapeutics market, accounting for the largest market share in 2024, followed by Europe and the Asia Pacific. The high prevalence of ovarian cancer, robust healthcare infrastructure, and the presence of leading market players contribute to North America's leadership. Europe benefits from strong government initiatives and widespread adoption of advanced diagnostic technologies, while the Asia Pacific region is poised for the fastest growth due to rising healthcare investments, increasing awareness, and improving access to medical care. Latin America and the Middle East & Africa are also witnessing steady growth, albeit from a lower base, driven by gradual improvements in healthcare infrastructure and cancer awareness programs.

BackgroundOvarian cancer contributes significantly to the morbidity and mortality rates for women worldwide. As observed with other types of cancer, health disparities disproportionately affect ovarian cancer incidence rates and outcomes, especially in African American and older women. However, the trends in ovarian cancer mortality rates up until 2023 with regard to various demographic identifiers have not been fully elucidated, which this study aims to rectify.MethodsMortality trends due to malignant neoplasms of the ovary in individuals 25 and older in the US from 1999 to 2023 were analyzed using the Centers for Disease Control Wide Ranging Online Data for Epidemiological Research (CDC WONDER) database. Trends in age-adjusted mortality rate (AAMR) were analyzed on the basis of race, 10-year age-group, region and urban/rural designation.ResultsBetween 1999 and 2023, the AAMR related to malignant neoplasms of the ovary fell from 14.62 in 1999 to 9.52 in 2023. All races analyzed saw a decrease in overall mortality related to malignant neoplasms of the ovary, with the largest decrease being observed in White patients (AAPC: -1.78). Regionally, the Northeast (AAPC: -1.95), Midwest (AAPC: -1.99), South (AAPC: -1.72), and West (AAPC: -1.73) regions of the United States (US) all saw reduced ovarian neoplasm mortality rates. Similarly, rates also decreased in urban (AAPC: -1.83) and rural (AAPC: -1.75) localities, as well as in each ten-year age category analyzed, with the largest decrease seen in the 55–64 years old category (AAPC: -2.15). States such as Delaware, South Carolina, and Idaho experienced some of the largest decreases in AAMR, whereas the District of Columbia saw an increase in AAMR during this period.ConclusionsOver the last twenty-years, mortality rates for malignant neoplasms of the ovary have declined, with the largest decreases being seen in White patients, those residing in the Midwest, urban locality, and women between 55–64 years olds. While mortality rates have declined, health disparities still continue to negatively affect ovarian cancer outcomes, and more research is needed to improve accessibility, availability, and affordability of care for patients.

Yearly citation counts for the publication titled "Epithelial ovarian cancer in younger age versus older age groups: Survival and clinicopathological features".

The Ovarian Cancer Diagnostics & Therapeutics Market report segments the industry into By Cancer Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, Other Cancer Types), By Modality (Diagnosis, Therapeutics), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America). Get five years of historical insights as well as forecasts.

The North America Ovarian Cancer Diagnostics Market report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

The Asia-Pacific Ovarian Cancer Diagnostics and Therapeutics Market Report Segments the Industry Into by Cancer Type (Epithelial Ovarian Tumors, Ovarian Germ Cell Tumors, and More), by Diagnosis (Blood Tests, PET, CT Scan, and More), by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, and More), and Geography (China, Japan, India, and More).

Ovarian Cancer Multimarker Algorithms Market Outlook

According to our latest research, the global ovarian cancer multimarker algorithms market size reached USD 1.48 billion in 2024, reflecting robust demand for advanced diagnostic solutions in oncology. The market is projected to expand at a CAGR of 11.2% from 2025 to 2033, reaching a value of USD 4.14 billion by 2033. This growth is primarily driven by the rising incidence of ovarian cancer worldwide and the increasing adoption of multimarker algorithms for early detection and accurate disease management. These algorithms are revolutionizing the diagnostic landscape by integrating multiple biomarkers and advanced analytics, thus enhancing sensitivity and specificity in ovarian cancer detection.

A critical growth factor for the ovarian cancer multimarker algorithms market is the persistent increase in ovarian cancer prevalence across the globe. Ovarian cancer remains one of the most lethal gynecological malignancies, often diagnosed at advanced stages due to the lack of specific symptoms and effective early screening tools. The adoption of multimarker algorithms, which combine biomarkers such as CA-125, HE4, LDH, and beta-hCG, is significantly improving early detection rates and clinical outcomes. Healthcare systems are increasingly prioritizing investments in advanced diagnostics, fueled by supportive government initiatives and heightened awareness among clinicians and patients regarding the benefits of early and accurate diagnosis.

Technological advancements in diagnostic kits, analyzers, and algorithmic software have further propelled the market’s growth trajectory. The integration of artificial intelligence and machine learning into multimarker algorithms is enabling real-time data analysis and interpretation, facilitating faster and more reliable results. Major industry players are actively collaborating with research institutes to develop next-generation platforms that can process complex datasets while maintaining high accuracy. Additionally, regulatory approvals for new diagnostic products and algorithms are accelerating market entry and adoption, particularly in developed economies where healthcare infrastructure is highly advanced.

Another vital growth driver is the expanding application of multimarker algorithms beyond diagnosis to include screening, prognosis, and monitoring of ovarian cancer. The versatility of these algorithms allows for risk stratification, disease progression assessment, and treatment response evaluation, thereby supporting personalized medicine approaches. As the paradigm shifts towards value-based healthcare, payers and providers are increasingly recognizing the cost-effectiveness and clinical utility of multimarker algorithms, further fostering market expansion. The growing trend of decentralizing diagnostics, with an emphasis on point-of-care and home-based testing, is also expected to create new opportunities for market players in the coming years.

From a regional perspective, North America currently dominates the ovarian cancer multimarker algorithms market, accounting for the largest revenue share in 2024, followed by Europe and Asia Pacific. The high prevalence of ovarian cancer, well-established healthcare infrastructure, and rapid adoption of innovative diagnostic technologies are key factors supporting market leadership in North America. Europe is witnessing steady growth, driven by increasing government funding for cancer research and rising awareness about early detection. The Asia Pacific region is anticipated to exhibit the fastest CAGR during the forecast period, propelled by improving healthcare access, rising cancer burden, and growing investments in diagnostic infrastructure across emerging economies such as China and India.

Product Type Analysis

The product type segment of the ovarian cancer multimarker algorithms market is broadly categorized into diagnostic kits, analyzers, and software. Diagnostic kits form the backbone of this market, offering ready-t

ObjectivesOvarian tumors are among the most prominent gynecological malignancies and have a poor prognosis. Immunotherapy has undergone incredible progress in the past two decades. Our study aimed to use a bibliometric approach to identify research trends in ovarian cancer immunotherapy.MethodsLiterature on this topic published from 2000–2020 was retrieved from the Web of Science Core Citation database and analyzed using the bibliometric analysis software VOSviewer and CiteSpace.ResultsA total of 1729 articles on ovarian cancer immunotherapy published from January 2000 to December 2020 were identified. The number of published articles increased each year, from 40 in 2000 to 209 in 2020. These publications were from 61 countries, and the USA showed a dominant position in publication output, total citations, and average number of citations per paper. Co-citation networks revealed 14 subtopics. ‘PD-L1 expression,’ ‘tumor reactive til,’ and ‘parp inhibitor’ are the current potential subtopics. Furthermore, we determined research trends according to the timeline analysis.ConclusionOur study exhaustively describes the development and summarizes the research trends of ovarian cancer immunotherapy over the past 20 years.

Yearly citation counts for the publication titled "Screening and Diagnosis of Ovarian Cancer—High Risk".